NRG Energy Inc vs Twist Bioscience Corp — how do they compare? NRG Energy Inc trades at $116.91 (market cap $25.15B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: NRG Energy Inc is far larger — about 3× Twist Bioscience Corp's market cap, and NRG Energy Inc pays a 1.59% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NRG | TWST | |
|---|---|---|
Market Cap | $25.15B | $8.42B |
Sector | Utilities | Health |
52-Week High | $184.03 | $153.10 |
52-Week Low | $109.51 | $24.16 |
Enterprise Value | $49.10B | $8.35B |
Dividend Yield | 1.59% | — |
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $119.64, up 0.52% with a bullish technical signal despite recent earnings misses. The stock shows strong profitability metrics including 26.77% ROE and 2.56% net margin, supported by $30.71B revenue in 2025. Recent developments include a transformative 1.2 GW Texas data-center power project and LS Power acquisition, driving long-term growth expectations. Cash flow trends show volatility with 2025 net cash flow of $3.83B followed by projected 2026 outflow of -$264M.
Wall Street maintains strong bullish sentiment with 69% buy ratings and $201.29 consensus target, representing 68% upside. Key risks include rising interest costs impacting earnings, elevated debt levels at 56.42% debt-to-asset ratio, and execution challenges with major capital projects. The data center expansion strategy offers significant growth potential but requires careful monitoring of capex and leverage management.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Trailing returns across standard periods
Latest headlines on both assets
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →